Association between miRNA expression profiles and polymorphisms of dihydropyrimidine dehydrogenase drug-metabolizing gene in patients with colorectal cancer receiving 5-fluorouracil.

ABSTRACT: 5-Fluorouracil (5-FU) is widely used for colorectal cancer (CRC) treatment. Its administration is challenged by wide variability in patient toxicity. Genetic polymorphisms in dihydropyrimidine dehydrogenase (DYPD) and circulating microRNAs (miRNAs) are promising biomarkers to predict 5-FU-associated toxicity. The present study aimed to assess the association between miRNA expression profiles, three DPYD polymorphisms (85T>C, 1627A>G, 1896T>C) and hematological toxicity in patients with CRC receiving 5-FU. A total of 48 patients with CRC treated with 5-FU-based regimens were prospectively enrolled. Genotyping for DPYD 85T>C, 1627A>G and 1896T>C was performed by TaqMan Realtime PCR. Hematological toxicity was assessed by Common Terminology Criteria for Adverse Events v5.

SUBMITTER: Phannasil P 

PROVIDER: S-EPMC12464475 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature